TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Rory M. Shallis, Naval G. Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H. Wei, David A. Sallman, Amer M. Zeidan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
Journalcancer
Volume129
Issue number2
DOIs
StatePublished - Jan 15 2023

Funding

The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health (grant P30 CA016672).

Keywords

  • TP53
  • acute myeloid leukemia (AML)
  • cutoff
  • excess blasts
  • myelodysplastic syndrome (MDS)
  • p53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity'. Together they form a unique fingerprint.

Cite this